Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of CC-92480 With or Without Dexamethasone in Relapsed and Refractory Multiple Myeloma
jRCT2061200056Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2021
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
01
Overview
Phase 2, open-label trial of mezigdomide in multiple myeloma (MM) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Safety (adverse events and clinical assessments), Pharmacokinetics of CC-92480 and R-enantiomer and 2 more. Started Sep 2021; status: completed.
02
Drugs
mezigdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2061200056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061200056.